Reduced‑dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series

Pol Arch Intern Med. 2021 Aug 30;131(7-8):762-765. doi: 10.20452/pamw.16024. Epub 2021 Jun 2.

Authors

Anna Weronska¹, Elżbieta Papuga-Szela², Elzbieta Broniatowska¹, Anetta Undas³

Affiliations

¹ Faculty of Medicine and Health Science, Andrzej Frycz Modrzewski Krakow University, Kraków, Poland
² John Paul II Hospital, Kraków, Poland
³ John Paul II Hospital, Kraków, Poland; Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland. mmundas@cyf-kr.edu.pl

PMID: 34075737
DOI: 10.20452/pamw.16024

No abstract available

MeSH terms

Anticoagulants / therapeutic use
Dabigatran* / adverse effects
Humans
Liver Cirrhosis / complications
Liver Cirrhosis / drug therapy
Pyrazoles
Pyridones / adverse effects
Venous Thromboembolism* / drug therapy

Substances

Anticoagulants
Pyrazoles
Pyridones
apixaban
Dabigatran